Argenx Completes Acquisition of Forte Biosciences

09:04 AM EDT, 08/27/2026 (MT Newswires) -- Argenx (ARGX) said Thursday it has completed its acquisition of Forte Biosciences (FBRX) for $77 per share. Forte is now a subsidiary of argenx and Forte's common stock will no longer be listed or traded on the Nasdaq Capital Market, according to a statement. About 19.9 million shares of Forte common stock were validly tendered and not validly withdrawn, representing about 87.13% of its issued and outstanding shares of common stock as of Aug. 26, including shares owned by argenx and its affiliates, the statement said.